Brokerages Expect Ascendis Pharma A/S (ASND) to Post -$0.89 EPS

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to post ($0.89) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Ascendis Pharma A/S’s earnings, with estimates ranging from ($1.00) to ($0.76). Ascendis Pharma A/S reported earnings per share of ($0.55) during the same quarter last year, which would indicate a negative year-over-year growth rate of 61.8%. The company is scheduled to announce its next quarterly earnings results on Wednesday, March 28th.

On average, analysts expect that Ascendis Pharma A/S will report full year earnings of ($3.88) per share for the current fiscal year, with EPS estimates ranging from ($4.25) to ($3.55). For the next fiscal year, analysts anticipate that the firm will report earnings of ($3.50) per share, with EPS estimates ranging from ($4.17) to ($2.86). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, November 16th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.37). Ascendis Pharma A/S had a negative net margin of 4,687.42% and a negative return on equity of 64.10%.

A number of brokerages have commented on ASND. HC Wainwright reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research note on Friday, January 19th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $60.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday, January 17th. BidaskClub upgraded shares of Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 25th. Zacks Investment Research cut shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, Wedbush restated an “outperform” rating and set a $62.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, February 6th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $51.83.

Shares of Ascendis Pharma A/S (ASND) traded down $0.94 during mid-day trading on Friday, reaching $50.10. 334,331 shares of the company’s stock were exchanged, compared to its average volume of 165,884. The firm has a market capitalization of $1,820.00, a PE ratio of -12.43 and a beta of 1.02. Ascendis Pharma A/S has a 12-month low of $21.95 and a 12-month high of $55.00.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $194,000. Aperio Group LLC acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $241,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth about $269,000. Jane Street Group LLC acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $352,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $372,000. Institutional investors own 78.94% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Brokerages Expect Ascendis Pharma A/S (ASND) to Post -$0.89 EPS” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/11/brokerages-expect-ascendis-pharma-a-s-asnd-to-post-0-89-eps.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply